Phase 1, Open-label, Two-Cohort Study of Orally Administered PAX-1 in Patients with Moderate COVID-19
A Randomised, Double-blind, Parallel-Group, Placebo-Controlled Phase II Study to Assess the Opioid-Sparing Activity of PAX-1 in Patients with Persistent Cancer Pain.
100 Clinical Results associated with Komipharm International Australia Pty Ltd.
0 Patents (Medical) associated with Komipharm International Australia Pty Ltd.
100 Deals associated with Komipharm International Australia Pty Ltd.
100 Translational Medicine associated with Komipharm International Australia Pty Ltd.